Janux Therapeutics, Inc.

JANX Healthcare Biotechnology

Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.

16.49 0.83 −4.79%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
−7.8×
Dividend yield
—
F-score
2/9
Altman Z
11.61
Beneish M
n/a
Dividend safety
n/a
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — — 4 4 2
P/E ratio
— — — 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
— — — 21.34 7.61 7.69 45.12 11.61
P/S ratio
— — — 127.65 67.51 60.01 271.80 44.23
Altman Z″-Score (non-manufacturers)
— — — 33.80 11.25 13.09 32.65 26.48
P/FCF ratio
— — — 0.00 0.00 0.00 0.00 0.00
P/Operating CF
— — — (44.29) (48.80) (48.99) (172.07) (29.96)
P/B ratio
— — — 1.27 1.81 1.41 2.81 0.89
Price to Tangible BV
— — — 1.27 1.81 1.41 2.81 0.89
EV/Sales
— — — 24.55 29.54 17.45 174.98 (5.76)
EV/EBITDA
— — — 0.00 0.00 0.00 0.00 0.64
EV/Operating CF
— — — (5.26) (5.93) (2.79) (42.29) 1.35
EV/FCF
— — — (4.84) (5.15) (2.69) (41.94) 1.34
Quick Ratio
— 0.14 4.97 29.30 19.81 26.40 58.72 38.67
Current Ratio
— 0.14 5.05 29.46 20.14 26.80 59.21 39.04
Net Debt/EBITDA
— 0.17 1.62 11.37 4.78 4.37 9.55 5.58
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
— 0.00 0.00 0.02 0.02 0.02 0.01 0.01
Operating CF/Net income
— 0.96 0.64 0.52 0.68 0.87 0.64 0.72
Capex/Depreciation
— 0.00 0.00 25.12 4.80 0.32 0.04 0.07
Interest Coverage
— (16.18) (23.51) (128.13) (16.64) — — —
ROE
— 35.46% 60.08% (18.58%) (18.36%) (17.53%) (10.09%) (11.48%)
ROA
— (1,179.38%) (80.30%) (16.50%) (16.96%) (15.66%) (9.57%) (11.02%)
ROIC
— 0.00% 0.00% 0.00% 0.00% (14,209.31%) 0.00% 0.00%
Return on Tangible Assets
— 101.42% (52.04%) (8.94%) (19.52%) (16.98%) (6.76%) (11.90%)
Average Days of Receivables
— — 0.00 0.00 0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
— 0.00% 0.00% 721.39% 620.54% 679.48% 645.90% 1,258.96%
Selling, General and Administrative Expense of Revenue
— 0.00% 0.00% 284.00% 258.50% 323.39% 387.67% 417.71%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 0.00% 0.00% 189.99% 199.76% 247.49% 311.86% 402.21%
Graham Net Nets
— — — 0.78 0.50 0.65 0.35 1.09
Graham Number
— — — 0.00 0.00 0.00 0.00 0.00
Earnings Yield
— — — (16.55%) (10.84%) (12.16%) (2.39%) (13.26%)
Free Cash Flow Yield
— — — (3.98%) (8.49%) (10.81%) (1.53%) (9.74%)
Revenue per Share
— 0.00 0.00 0.15 0.21 0.18 0.20 0.16
Operating CF per Share
— (5.72) (4.77) (0.72) (1.03) (1.15) (0.82) (1.33)
Capex per Share
— 0.00 0.00 (0.06) (0.16) (0.04) (0.01) (0.02)
Free Cash Flow per Share
— (5.72) (4.77) (0.78) (1.19) (1.19) (0.82) (1.34)
Cash per Share
— 0.98 8.54 15.94 7.89 7.82 19.07 15.60
Shareholders Equity per Share
— (5.90) 7.63 15.57 7.73 7.82 19.03 15.44
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— (5.90) 7.63 15.57 7.73 7.82 19.03 15.44
Free Cash Flow
— (3.83) (4.37) (18.46) (49.37) (52.42) (44.17) (83.28)
Working Capital
— (3.97) 12.88 364.22 315.93 336.21 1,016.21 950.89
Capital Expenditures
— — — (1.48) (6.44) (1.85) (0.36) (1.04)
Net Current Asset Value
— (3.97) 6.83 363.52 289.17 313.18 994.93 931.14
EV/EBIT
— — — 0.00 0.00 0.00 0.00 0.71
Capex to Sales
— — — 0.41 0.75 0.23 0.03 0.10
Price to Operating Income
— — — 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
— 0.29 0.08 (0.04) (0.19) (0.82) (1.75) (4.04)
Cash ROIC
— 116.35% (29.52%) (2.49%) (7.62%) (7.62%) (2.16%) (4.33%)
Accounts Receivable Turnover
— — 0.00 0.89 19.14 0.00 0.00 0.00
Accounts Payable Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— 0.00 0.00 0.00 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— 0.00 0.00 0.00 0.00 — — —
Average Receivables
— — 4.10 4.10 0.45 — — —
Average Payables
— 0.35 0.35 1.44 2.31 2.29 3.23 4.50
Average Assets
— 0.34 8.45 198.02 371.92 372.21 720.96 1,031.54
Average Common Equity
— (11.29) (11.29) 175.84 343.53 332.54 683.57 989.80

Fold the line items

Columns are period end dates